Healius Ltd (ASX: HLS)
A note out of the Macquarie equities desk reveals that its analysts have retained their outperform rating and lifted the price target on this healthcare company’s shares to $4.10. Macquarie was impressed with Healius’ first quarter update, which was boosted by strong demand for COVID-19 testing. The broker notes that this was supported by other parts of the business, which performed positively. Looking ahead, Macquarie believes Healius has plenty of growth opportunities and remains positive on its outlook. While not my top pick in the sector, I do think it could be a good option for investors.
Healius Ltd (ASX: HLS)A note out of the Macquarie equities desk...
Add HLS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.000(0.00%) |
Mkt cap ! $1.147B | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.60 | $1.54 | $2.060M | 1.320M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3857 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 12262 | 4 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| HLS (ASX) Chart |